PANDIA IRIS: Patients With Diabetes and Kidney Failure, an Interdisciplinary Medication Adherence Support Program

NACompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

April 14, 2016

Primary Completion Date

December 20, 2022

Study Completion Date

December 20, 2022

Conditions
Diabetes Mellitus, Type 2Renal Insufficiency, Chronic
Interventions
OTHER

Inteprofessional medication adherence support program (IMAP)

In addition to usual care, patients participate in a medication adherence support program combining an Electronic Monitoring system (EM, named MEMS®; Aardex Ltd) and motivational semi-structured interviews. This programm is done by the Unisanté's community pharmacists, in coordination with medical and nurse staff , to support medication adherence and to promote continuity of care. The intervention is held at the Unisanté's community pharmacy. For patients not speaking french, english, or italien, the interviews will be done with a interpreter.

Trial Locations (2)

1011

Centre Hospitalier Universitaire Vaudois, Lausanne

Unisante, Lausanne

All Listed Sponsors
collaborator

pharmaSuisse

UNKNOWN

collaborator

santésuisse

UNKNOWN

collaborator

Curafutura

UNKNOWN

lead

Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland

OTHER

NCT04190251 - PANDIA IRIS: Patients With Diabetes and Kidney Failure, an Interdisciplinary Medication Adherence Support Program | Biotech Hunter | Biotech Hunter